Last reviewed 2026-04-23 · How we verify

(P) DWC202207

DWC202207 is a drug that targets the PD-1 receptor.

DWC202207 is a drug that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

At a glance

Mechanism of action

By binding to the PD-1 receptor, DWC202207 blocks the interaction with its ligands, PD-L1 and PD-L2, thereby releasing the PD-1 mediated inhibition of T-cell activation and proliferation.

Approved indications

• Non-small cell lung cancer, PD-L1 positive
• Head and neck squamous cell carcinoma

Common side effects

• Pneumonitis
• Hypothyroidism
• Hyperthyroidism

Key clinical trials

• A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.